BS_WH5HDE0A
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 8.672798948751643
- age_years
- 0.608
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.527
- G2M_CHECKPOINT+0.508
- MYC_TARGETS_V1+0.410
- PANCREAS_BETA_CELLS+0.403
- MITOTIC_SPINDLE+0.295
- SPERMATOGENESIS+0.262
- MYC_TARGETS_V2+0.220
- HEDGEHOG_SIGNALING+0.160
- DNA_REPAIR+0.150
- OXIDATIVE_PHOSPHORYLATION+0.138
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.742
- INTERFERON_GAMMA_RESPONSE-0.643
- INFLAMMATORY_RESPONSE-0.508
- ALLOGRAFT_REJECTION-0.499
- IL6_JAK_STAT3_SIGNALING-0.483
- TNFA_SIGNALING_VIA_NFKB-0.482
- IL2_STAT5_SIGNALING-0.447
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- BILE_ACID_METABOLISM-0.419
- NOTCH_SIGNALING-0.394
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_AM70R8RG | medulloblastoma | — | 0.972 |
| 2 | BS_AMZ70B6F | medulloblastoma | — | 0.968 |
| 3 | BS_S69QZAJR | medulloblastoma | — | 0.962 |
| 4 | BS_QWNBZ9RJ | Embryonal tumors | — | 0.961 |
| 5 | TCGA-C4-A0EZ-01A-21R-A24X-07 | — | — | 0.958 |
| 6 | BS_FCAKKZ20 | medulloblastoma | — | 0.954 |
| 7 | BS_7XQRH69M | medulloblastoma | — | 0.953 |
| 8 | BS_EFE4YEK3 | medulloblastoma | — | 0.950 |
| 9 | BS_Y8D1F5WW | medulloblastoma | — | 0.949 |
| 10 | BS_3F5PR9GS | medulloblastoma | — | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.527 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.508 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.403 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.295 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.262 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.138 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.005 | Inavolisib | — uncovered |